Dual Biologics May End Daily Pills Post-Kidney Transplant

Published Date: 02 Mar 2026

A novel dual biologic regimen combining dazodalibep and belatacept is well tolerated and could enable more than half the kidney transplant recipients to avoid broader metabolic pathway inhibitors.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot